ÇмúÀÚ·á½Ç

  • ÇмúÀÚ·á½Ç
  • Çмúµ¿¿µ»ó
  • °úÇмҽÄ
  • ³í¼úÀÚ·á½Ç
  • µ¿¾Æ¸®ÀÚ·á½Ç
ÅëÇÕ°Ë»ö

°úÇмҽÄ

Áٱ⼼Æ÷ ÁÖÀÔ-³úÁ¹Áß È¯ÀÚ ¸¶ºñ »ç¶óÁ®

°Ô½ÃÀÏ 2016-06-03 13:30  |  ÃÖÁ¾¼öÁ¤ 2016-06-03 13:32
    Clinical Outcomes of Transplanted Modified Bone Marrow–Derived Mesenchymal Stem Cells in Stroke: A Phase 1/2a Study

 

Abstract

Background and Purpose—Preclinical data suggest that cell-based therapies have the potential to improve stroke outcomes.

Methods—Eighteen patients with stable, chronic stroke were enrolled in a 2-year, open-label, single-arm study to evaluate the safety and clinical outcomes of surgical transplantation of modified bone marrow–derived mesenchymal stem cells (SB623).

Results—All patients in the safety population (N=18) experienced at least 1 treatment-emergent adverse event. Six patients experienced 6 serious treatment-emergent adverse events; 2 were probably or definitely related to surgical procedure; none were related to cell treatment. All serious treatment-emergent adverse events resolved without sequelae. There were no dose-limiting toxicities or deaths. Sixteen patients completed 12 months of follow-up at the time of this analysis. Significant improvement from baseline (mean) was reported for: (1) European Stroke Scale: mean increase 6.88 (95% confidence interval, 3.5–10.3;P<0.001), (2) National Institutes of Health Stroke Scale: mean decrease 2.00 (95% confidence interval, −2.7 to −1.3; P<0.001), (3) Fugl-Meyer total score: mean increase 19.20 (95% confidence interval, 11.4–27.0; P<0.001), and (4) Fugl-Meyer motor function total score: mean increase 11.40 (95% confidence interval, 4.6–18.2; P<0.001). No changes were observed in modified Rankin Scale. The area of magnetic resonance T2 fluid-attenuated inversion recovery signal change in the ipsilateral cortex 1 week after implantation significantly correlated with clinical improvement at 12 months (P<0.001 for European Stroke Scale).

Conclusions—In this interim report, SB623 cells were safe and associated with improvement in clinical outcome end points at 12 months.

³í¹®Ãâó: http://stroke.ahajournals.org/content/early/2016/06/02/STROKEAHA.116.012995.abstract

 

 

Áٱ⼼Æ÷ ÁÖÀÔ-³úÁ¹Áß È¯ÀÚ ¸¶ºñ »ç¶óÁ®

±âÁõµÈ °ñ¼öÁٱ⼼Æ÷°¡ ³ú¿¡ Á÷Á¢ ÁÖÀÔµÈ ¸¸¼º ¸¶ºñ ³úÁ¹Áß È¯ÀÚµéÀÌ ´Ü±â°£¿¡ ¸¶ºñ°¡ »ç¶óÁö´Â µî ³î¶ó¿î È¿°ú°¡ ³ªÅ¸³ª ¹Ì±¹ÀÇ ½Å°æ°úÇа踦 ÈïºÐ½ÃÅ°°í ÀÖ´Ù°í ¿ö½ÌÅÏ Æ÷½ºÆ® ÀÎÅͳÝÆÇ µîÀÌ 2ÀÏ º¸µµÇß´Ù.

½ºÅÄÆÛµå ´ëÇÐ ÀÇ°ú´ëÇÐ ½Å°æ¿Ü°ú°úÀå °³¸® ½ºÅ¸Àιö±× ¹Ú»ç´Â ³úÁ¹Áß ¹ß»ý 6°³¿ùÀÌ °æ°úÇØ ´õ ÀÌ»ó ¸¶ºñ°¡ °³¼±µÉ °¡´É¼ºÀÌ ¾ø´Â ¸¸¼º ¸¶ºñ ȯÀÚ 18¸í(Æò±Õ¿¬·É 61¼¼)¿¡°Ô °ñ¼öÁٱ⼼Æ÷¸¦ ³ú¿¡ Á÷Á¢ ÁÖÀÔÇÑ °á°ú 7¸íÀÌ 1~12°³¿ù »çÀÌ¿¡ ¿îµ¿, ¾ð¾î, ½Ã°¢, ÀÏ»ó»ýÈ° ±â´ÉÀÌ Å©°Ô °³¼±µÇ´Â ³î¶ó¿î È¿°ú°¡ ³ªÅ¸³µ´Ù°í ¹ßÇ¥Çß´Ù.

³úÁ¹ÁßÀº ÀϹÝÀûÀ¸·Î ¹ß»ý ÈÄ ¹ÌºñÁõ»óÀÌ Á¶±Ý¾¿ ³ª¾ÆÁöÁö¸¸ 6°³¿ùÀÌ °æ°úÇÏ¸é ´õ ÀÌ»ó °³¼±µÇÁö ¾Ê´Â´Ù.  ¸¶ºñ °³¼±Àº ¿òÁ÷ÀÌÁö ¾Ê´ø ¾öÁö¼Õ°¡¶ôÀ» ²¿¹°°Å¸®°Ô µÈ Á¤µµ°¡ ¾Æ´Ï¶ó ²Ä¦ ¸ø ÇÏ´ø ÆÈ°ú ´Ù¸®¸¦ ¿Ã¸®°í °ÈÁö ¸øÇÏ´ø »ç¶÷ÀÌ °È°Ô µÈ °ÍÀ̶ó¸é¼­ ½Ã¼úÆÀ¸¶Àúµµ ¾î¸®µÕÀýÇÒ Á¤µµ¶ó°í ½ºÅ¸Àιö±× ¹Ú»ç´Â ¹àÇû´Ù.

ÈÙü¾î¿¡ ÀÇÁöÇÏ´ø 71¼¼ ȯÀÚ´Â ÀϾ °È°Ô µÆ°í ³úÁ¹Áß ÈÄ 2³âÀÌ °æ°úÇÑ 39¼¼ ȯÀÚ´Â °È±â°¡ ¾î·Æ°í ¸»ÀÌ ¾î´­Çߴµ¥ ½Ã¼ú ÈÄ ¸»µµ ³ª¾ÆÁö°í Àüº¸´Ù ÈξÀ Àß °È°Ô µÆ´Ù.

°ñ¼öÁٱ⼼Æ÷´Â 2¸íÀÇ ±âÁõÀÚÀÇ °ñ¼ö¿¡¼­ äÃëµÈ Áß°£¿±Áٱ⼼Æ÷(mesenchymal stem cell)¿¡ ±â´ÉÀ» º¸°­ÇÑ ¼¼Æ÷(SB623)¸¦ »ç¿ëÇß´Ù. ÀÌ Áٱ⼼Æ÷´Â ȯÀÚµéÀÇ µÎ°³°ñ¿¡ ¶ÕÀº ÀÛÀº ±¸¸ÛÀ» ÅëÇØ ³úÁ¹ÁßÀ¸·Î ¼Õ»óµÈ ºÎÀ§ ÁÖº¯¿¡ Á÷Á¢ ÁÖÀԵƴÙ. ½Ã¼úÀº ³ú¼ö¼úÄ¡°í´Â ºñ±³Àû °£´ÜÇØ È¯ÀÚµéÀº ½Ã¼ú ³»³» ÀǽÄÀ» À¯ÁöÇßÀ¸¸ç ½Ã¼ú ´çÀÏ Åð¿øÇß´Ù. ºÎÀÛ¿ëÀº ÀϽÃÀûÀÎ µÎÅë, ¿À½É, ±¸Åä¿´°í ½É°¢ÇÑ ºÎÀÛ¿ëÀº ¾ø¾ú´Ù. ȯÀÚ ÇÑ ¸íÀº ³ú¿¡ ¹°ÀÌ Â÷¿Ã¶úÀ¸³ª ¹°À» »©ÀÚ ¾Æ¹«·± ¹®Á¦°¡ ¾ø¾ú´Ù. Áß°£¿±Áٱ⼼Æ÷´Â ±ÙÀ°, ÈûÁÙ, Áö¹æÀ¸·Î ºÐÈ­ÇÒ ¼ö ÀÖ´Â Àü±¸¼¼Æ÷ÀÌÁö¸¸ ÀÌ ½Ã¼ú·Î ¿øÄ¡ ¾Ê´Â Á¶Á÷À¸·Î ºÐÈ­Çϰųª Á¾¾çÀ» Çü¼ºÇÏÁö´Â ¾Ê¾Ò´Ù. ÀÌ Áٱ⼼Æ÷´Â ȯÀÚÀÚ½ÅÀÌ ¾Æ´Ñ ³²ÀÇ °ÍÀ̾úÁö¸¸ ¸é¿ª°ÅºÎ¹ÝÀÀÀ» ÀÏÀ¸Å°Áö´Â ¾Ê¾Ò´Ù. ¿ÀÈ÷·Á ¸é¿ªÃ¼°è¸¦ Àû±Ø ¾ïÁ¦ÇÏ´Â °Í °°¾Ò´Ù. ±×·¡¼­ ½Ã¼ú ȯÀڵ鿡°Ô´Â ¸é¿ª¾ïÁ¦Á¦°¡ Åõ¿©µÇÁö ¾Ê¾Ò´Ù.

½Ã¼úÀ» ÁöÈÖÇÑ ½ºÅ¸Àιö±× ¹Ú»ç´Â ȯÀÚ¿¡ ÁÖÀÔµÈ Áٱ⼼Æ÷°¡ Áö±Ý±îÁö »ý°¢ÇØ¿Â °Íó·³ ½Å°æ¼¼Æ÷·Î ºÐÈ­ÇÑ °Í °°Áö´Â ¾Ê°í ³úÀÇ ÀÚ°¡¼ö¸® ±â´ÉÀ» Çâ»ó½ÃÅ°´Â ±× ¾î¶² »ýÈ­ÇÐÀû °úÁ¤À» Ã˹߽ÃŲ °ÍÀ¸·Î º¸ÀÎ´Ù°í ¼³¸íÇß´Ù. ¸»ÇÏÀÚ¸é ¼ºÀÎÀÇ ³ú¸¦ ȸº¹ÀÌ Àß µÇ´Â ½Å»ý¾ÆÀÇ ³ú·Î ¹Ù²Ù¾ú´Ù°í ÇÒ ¼ö ÀÖ´Ù´Â °ÍÀÌ´Ù.

ÀÌ °á°ú¿¡ ´ëÇØ Åػ罺 ´ëÇÐ ÀÇ°ú´ëÇÐ ½Å°æ¿Ü°ú Àü¹®ÀÇ ¼ð »õºñÃ÷ ¹Ú»ç´Â ´õ ¿¬±¸°¡ ÇÊ¿äÇϴٸ鼭 °¡Àå Å« Àǹ®Àº Áٱ⼼Æ÷°¡ º¯È­¸¦ ÀÚ±ØÇÑ °ÍÀÎÁö ¾Æ´Ï¸é ½Ã¼ú ÀÚü°¡ ¾î¶² ÇüÅÂÀÇ »ý¹°ÇÐÀû ¹ÝÀÀ ¶Ç´Â Çö󼼺¸ È¿°ú¸¦ ÀÏÀ¸Å² °ÍÀÌ ¾Æ´Ñ Áö¶ó°í ÁöÀûÇß´Ù. ¿¡¸ð¸® ´ëÇÐ ÀÇ°ú´ëÇÐÀÇ ½Å°æ¿Ü°ú Àü¹®ÀÇ ´ÏÄ÷¯½º ºÒ¸®½º ¹Ú»ç´Â ³ú¿¡´Â ÀçÈ°¼ºÈ­µÉ ¼ö ÀÖ´Â ±× ¾î¶² Àẹ¼º °æ·Î(latent pathway)°¡ ÀÖÀ» ¼ö ÀÖ´Ù´Â ÀÌ·ÐÀ» µÞ¹ÞħÇÏ´Â °ÍÀÎÁöµµ ¸ð¸¥´Ù°í ³íÆòÇß´Ù. À̹ø ÀÓ»ó½ÃÇèÀº È¿°ú°¡ ¾Æ´Ñ ¾ÈÀüÀ» È®ÀÎÇϱâ À§ÇÑ °ÍÀ̾ ¼Ò±Ô¸ð ȯÀÚ°¡ ´ë»óÀÌ µÆ´Ù.

½ºÅ¸Àιö±× ¹Ú»ç´Â ´õ ¸¹Àº ³úÁ¹Áß È¯ÀÚµéÀ» ´ë»óÀ¸·Î º»°ÝÀûÀÎ ÀÓ»ó½ÃÇèÀ» ÁøÇàÇϱâ À§ÇØ Âü°¡ ȯÀÚ¸¦ ¸ðÁýÇÏ°í ÀÖ´Ù. ½Ã¼ú ȯÀÚ´Â ÃÑ 156¸íÀÌ µÉ °ÍÀ̶ó°í ±×´Â ¹àÇû´Ù.

 

Çѱ۱â»çÃâó: http://www.dt.co.kr/contents.html?article_no=2016060302109954711006&naver=stand

ÄÚ¸àÆ® 0|Á¶È¸ 3,513
°Ô½Ã¹° ³»¿ë ÀμâÇϱâÀμâ| ¹°¸®Ä¡·á°ú
  • ¸ñ·Ï
  • ¾²±â

¹®¼­Æò°¡/¹®¼­´ã´çÀÚ

Q:ÇöÀç ÆäÀÌÁöÀÇ ¹®¼­ÀÇ ³»¿ë°ú »ç¿ëÆíÀǼº¿¡ ¸¸Á·ÇϽʴϱî?
ÀÇ°ßÀÔ·Â
QUICKÀÓ»óÁø´ÜÇнŰæ°èÀÓ»óÁø´ÜÇÐÁ¤Çü°èÀÎÅͳݰ­ÀǽÇAPTAStroke CenterPubMed±¹¸³Áß¾Óµµ¼­°ü´ëÇѹ°¸®Ä¡·á»çÇùȸTOP

Æ÷Ç׽à ºÏ±¸ ÈïÇØÀ¾ Ãʰ 146-1 Çаú»ç¹«½Ç 054)260-5531 / FAX. 054)260-5622
copyright¨Ï Physical Therapy of Sunlin College Since 2007. All Rights Reserved.

ÇØ´ç ÆäÀÌÁö·Î À̵¿ÇÕ´Ï´Ù.